System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Geneviève Loos is an expert in Radiotherapy at Centre Jean Perrin (France). Geneviève Loos has authored 37 publications, the most recent in 2027, and is an investigator in 4 clinical trials, 3 of them ongoing. SLR score: 144 (community average: 125). How the SLR is computed.

LeadR Profile

Geneviève Loos Centre Jean Perrin France
144 ScienceLeadR Reputation 144

Unlock

Register Login
Network Map

Radiotherapy

Subspecialties: Urology - Oncology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2010 - 2027
Source: PubMed

Centre Jean Perrin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 37

Citations

Citations: 217 1st author: 9 Last author: 1 Unique author: 0

Main journals

Cancer Radiother 14
Radiother Oncol 4
Eur Urol Oncol 3
Int J Radiat Oncol Biol Phys 3
J Clin Oncol 3

Best Journals

J Clin Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer.
PMID 42276876 — radiotherapy, intensity-modulated, radiotherapy, lymph nodes, androgens, neoplasms, prostate, urologic neoplasms, lymph, prostatic neoplasms, therapeutics		Eur Urol Oncol20260
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial.
PMID 42140755 — radiotherapy, lymph nodes, neoplasms, prostate, lymph, prostatic neoplasms, beds, therapeutics		Radiother Oncol20270
Pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer: outcomes of the CYGNUS multicentric retrospective study.
PMID 41864432 — retrospective studies, neoplasms, prostate, re-irradiation, prostatic neoplasms, therapeutics		Int J Radiat Oncol Biol Phys20260
Re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.01.005.
PMID 41708434 — registries, radiotherapy, prostate, therapeutics		Eur Urol Oncol20260
Physical activity and exercise in cervical cancer: a state-of-the-art review.
PMID 41649616 — exercise, uterine cervical neoplasms, neoplasms, therapeutics		Cancer Causes Control20260

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 2
N/A 1
Phase 2 1

By status:

Not yet recruiting 3
Active not recruiting 1

By type:

Interventional 4

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 4

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Treatment with darolutamide radiation therapy for patients with a castration resistant cancer and metastases detected by functional imaging
2023-509787-15-00 — radiotherapy, safety, lymph nodes, neoplasms, classification, prostate, positron emission tomography computed tomography, neoplasm metastasis, lymph, prostatic neoplasms, castration, therapeutics		Phase 3Not yet recruiting2025
An International Prospective Open label Multi center Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
2022-502956-29-00 — neoplasms, multiple chronic conditions, prostate, prostatic neoplasms, castration, membranes, male		Phase 3Not yet recruiting2024
Evaluation of the Stereotactic MR guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers
NCT07097064 — radiotherapy, pancreatic neoplasms, neoplasms, adenocarcinoma, radiotherapy, conformal, drug therapy, chemotherapy		Phase 2Not yet recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS